# Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

Study · id `cardio:ct-nct07210606` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07210606](<https://clinicaltrials.gov/study/NCT07210606>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07210606

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07210606. Randomized; double masking; primary purpose treatment. Start 2026-09-16 (actual); primary completion 2030-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07210606, source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)
- Started: 2026-09-16 (actual) (ClinicalTrials.gov record NCT07210606, source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT07210606, source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07210606, source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07210606, source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07210606-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
- Acronym: CSA-HF
- Condition: Sleep Disordered Breathing
- Condition: Able Bodied
- Intervention (Drug): Trazodone + positive airway pressure (PAP) therapy
- Intervention (Drug): Oxygen + positive airway pressure (PAP) therapy
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: f64b7ea855fb163b2ad2b10685630db5fc0d23594c400c7d44df35019c475b40
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
